Charles Jia-YIn Hou

Dr. Charles Jia-YIn Hou

Cardiovascular Center, MacKay Memorial Hospital, Taipei, Taiwan
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2013 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
FYFei-Shih Yang
Fei-Shih Yang
CYChun-Ho Yun
Chun-Ho Yun
TWTung-Hsin Wu
Tung-Hsin Wu
YHYa-Ching Hsieh
Ya-Ching Hsieh
HBHiram G Bezerra
Hiram G Bezerra
RCRicardo C Cury
Ricardo C Cury
Central obesity in relation to insulin resistance is strongly linked to the development of type 2 diabetes. However, data regarding the association between pericardial and peri-aortic adiposity, a potential estimate of visceral adipose tissue burden, and pre-diabetes status remains unclear.

8 April 2022 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
PCPo-Sheng Chen
Po-Sheng Chen
MLMeng Lee
Meng Lee
STSung-Chun Tang
Sung-Chun Tang
PHPo-Hsun Huang
Po-Hsun Huang
HYHung-I Yeh
Hung-I Yeh
YLYi-Heng Li
Yi-Heng Li
The previously published 2017 Taiwan Lipid Guidelines for High Risk Patients becomes the standard guidance of dyslipidemia management for patients with atherosclerotic cardiovascular disease (ASCVD) in Taiwan. New clinical trials of lipid lowering therapy were published successively after 2017. The study results changed the treatment concept of ASCVD. Therefore, an update focusing on the lipid treatment strategy for patients with ASCVD becomes necessary. In this focused update of the 2017 guideline, the treatment targets of low-density lipoprotein cholesterol (LDL-C) for patients with ASCVD were modified. The algorithm of LDL-C lowering therapy was revised. The recommendations in this focused update were made mainly based on the scientific evidence from recently published clinical trials and endorsed by the major medical societies in Taiwan.

5 November 2022 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
CCChing-Chi Chi
Ching-Chi Chi
YWYen-Wen Wu
Yen-Wen Wu
TCTing-Hsing Chao
Ting-Hsing Chao
CCChih-Chiang Chen
Chih-Chiang Chen
YCYi-Ju Chen
Yi-Ju Chen
Tsen-Fang TsaiTsen-Fang Tsai
Tsen-Fang Tsai
Psoriatic disease is a chronic inflammatory disorder with skin and joint manifestations. Due to the persistent inflammatory state exhibited by patients with psoriasis, multiple systemic comorbidities occur more frequently in patients with psoriasis than in the general population, and the risk of cardiovascular (CV) diseases is significantly increased. As the pathophysiology of psoriatic disease is becoming better understood, the sharing of underlying pathogenic mechanisms between psoriatic and CV diseases is becoming increasingly apparent. Consequently, careful attention to CV comorbidities that already exist or may potentially develop is needed in the management of patients with psoriasis, particularly in the screening and primary prevention of CV disease and in treatment selection due to potential drug-drug and drug-disease interactions. Furthermore, as the use of effective biologic therapy and more aggressive oral systemic treatment for psoriatic disease is increasing, consideration of the potential positive and negative effects of oral and biologic treatment on CV disease is warranted. To improve outcomes and quality of care for patients with psoriasis, the Taiwanese Dermatological Association, the Taiwanese Association for Psoriasis and Skin Immunology, and the Taiwan Society of Cardiology established a Task Force of 20 clinicians from the fields of dermatology, cardiology, and rheumatology to jointly develop consensus expert recommendations for the management of patients with psoriatic disease with attention to CV comorbidities.

22 June 2017 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Open access
PDF file
YHYi-Fan Hu
Yi-Fan Hu
CHCharles Jia-YIn Hou
Charles Jia-YIn Hou
CKChien-Feng Kuo
Chien-Feng Kuo
NWNai-Yu Wang
Nai-Yu Wang
AWAlice Ying-Jung Wu
Alice Ying-Jung Wu
HYHung-I Yeh
Hung-I Yeh
Background/Purpose The purpose of this study is to investigate the predominant clones of carbapenem-resistant Acinetobacter baumannii (CRAB) in our hospital in Taiwan by pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST) technique. Methods: We collected 108 non-duplicate A. baumannii clinical blood isolates from January 2012 to December 2013 in MacKay Memorial Hospital. PFGE and MLST were used for typing the A. baumannii isolates and for investigation of the predominant clones. Bacteria isolates were screened by polymerase chain reaction for the presence of the carbapenemase-encoding genes. Results: All 108 isolates were classified as 33 pulsotypes by PFGE. The predominant clones were pulsotype 10 (12.04%) in 2012 and pulsotype 8 (16.67%) in 2013, respectively. The 31 predominant pulsotype isolates were typed by MLST, and ST787 (54.84%) and ST455 (45.16%) were identified. All isolates carried blaOXA-51-like genes, and blaOXA-23-like genes was founded in 101 isolates (93.52%). Other identified resistance genes included blaOXA-24-like and blaOXA-IMP. Conclusion: To the best of our knowledge, this study is the first to describe the microbiological characteristics of CRAB ST787, which carried high genetic resistance to carbapenem, but remained susceptible to colistin. CRAB ST787 was the predominant clone in our hospital in the study period.

23 January 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
Hsiang-Yu LinHsiang-Yu Lin
Hsiang-Yu Lin
CCChih-Kuang Chuang
Chih-Kuang Chuang
Chung Lin LeeChung Lin Lee
Chung Lin Lee
MCMing-Ren Chen
Ming-Ren Chen
SKSung Kuo-Tzu
Sung Kuo-Tzu
Hsiang-Yu LinHsiang-Yu Lin
Hsiang-Yu Lin
Background: Mucopolysaccharidoses (MPSs) are a group of rare inherited metabolic disorders that can damage various organs, including the heart. Cardiac abnormalities have been observed in patients with all MPS types, with the most documented abnormalities being cardiac valvular regurgitation and stenosis, valvular thickening, and hypertrophic cardiomyopathy. Methods: Cardiac features of 53 Taiwanese patients with MPS (31 men and 22 women; age range 1.1–34.9 years; seven with MPS I, 16 with MPS II, nine with MPS III, 14 with MPS IVA, and seven with MPS VI) were evaluated using two-dimensional speckle-tracking echocardiography and conventional echocardiography. Results: The mean z scores of the global longitudinal strain (GLS), left ventricular mass index (LVMI), interventricular septum diameter in diastole (IVSd), left ventricular posterior wall diameter in diastole (LVPWd), and aortic diameter of the 53 patients with MPS were 1.71, 0.35, 1.66, 1.03, and 3.15, respectively. Furthermore, z scores >2 were identified in 45%, 13%, 40%, 13%, and 70% of the GLS, LVMI, IVSd, LVPWd, and aortic diameter, respectively. The most severe GLS was observed in those with MPS VI, followed by in those with MPS II and MPS I. The GLS z score was positively correlated with the LVMI z score (p < 0.01). Moreover, diastolic dysfunction (reversed ratio between early and late (atrial) ventricular filling velocity (E/A ratio < 1)) was identified in 12 patients (23%). Ejection and shortening fractions were abnormal in four (8%) and seven (13%) patients, respectively. Mitral regurgitation (MR) (92%) was the most common valvular heart disease, followed by aortic regurgitation (AR) (57%), mitral stenosis (MS) (21%), and aortic stenosis (AS) (15%). The z scores of the GLS and LVMI and severity scores of the MS, MR, AS, and AR were all positively correlated with increasing age (p < 0.05). Twenty patients (38%) had a left ventricular remodeling pattern. Conclusions: The most significant left ventricular myocardial deformation, hypertrophy and valvular heart disease were observed in the patients with MPS VI, II, and I, followed by those with MPS IV; in contrast, patients with MPS III had the mildest manifestations. Cardiac abnormalities in patients with MPS worsened with increasing age in accordance with the progressive nature of this disease.

10 March 2014 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
SKSung Kuo-Tzu
Sung Kuo-Tzu
CYChun-Ho Yun
Chun-Ho Yun
CHCharles Jia-YIn Hou
Charles Jia-YIn Hou
Chung-Lieh HungChung-Lieh Hung
Chung-Lieh Hung
Solitary papillary muscle (PM) hypertrophy is an unique type of hypertrophic cardiomyopathy (HCM), which is characterized by predominant papillary muscle hypertrophy sparing the rest of other left ventricular segments. It has recently drawn our attention about the mechanism of left ventricular mid-cavity obstruction and the influence of pressure gradient in the left ventricular outflow tract (LVOT), thus carries clinical importance.